Latest news with #Elion
Business Wire
3 days ago
- Business
- Business Wire
Elion Launches Integration of Coalition for Health AI ‘Nutrition Label' Within Vendor Marketplace
NEW YORK--(BUSINESS WIRE)--Elion, the healthcare technology research and intelligence platform for the AI era, announced today a new partnership with the Coalition for Health AI (CHAI), an industry-led coalition committed to developing industry best practices and frameworks to further innovation, safety and security for health AI. As part of this partnership, Elion is beta-launching a new feature: Abridged CHAI model cards now appear on select vendor profiles across its platform. 'As demand for AI adoption accelerates, healthcare leaders need a shared language and set of standards to evaluate solutions responsibly." To facilitate robust evaluation and accelerate adoption of successful AI solutions, CHAI developed an Applied Model Card framework, and recently established its first Model Card registry to support the rapid growth of model cards, or 'nutrition labels' for health AI, used to simplify procurement among health systems and solution providers. CHAI's model cards have created a more standard way to present foundational information about AI solutions, moving from powerpoint presentations to evidence and value-based procurement. Elion cofounder and CEO, Bobby Guelich, announced this new functionality at the CHAI Innovation Summit this week. Providing availability of CHAI's Model Cards through the Elion platform helps provider organizations quickly assess an AI model's intended use, oversight processes, and key performance considerations—all in the context of Elion's broader research and marketplace infrastructure. 'As demand for AI adoption accelerates, healthcare leaders need a shared language and set of standards to evaluate solutions responsibly,' said Guelich. 'CHAI's work in this area is foundational, and we're excited to bring their model cards into the day-to-day workflows of technology decision-makers through Elion's marketplace.' This integration represents the latest step in Elion's mission to equip health systems with the data, tools, and guidance needed to evaluate and implement emerging technologies. The current version includes model cards for a limited set of vendor solutions, with broader availability planned later this year. 'I am thrilled to see our health AI nutrition label advancing effective and responsible health AI,' said Brian Anderson, CHAI's CEO. 'By integrating this with Elion, we are enabling health system AI solution evaluation and allowing decision-makers to easily access Model Cards. CHAI is driven by the expertise of our members and the feedback of our broader health ecosystem and the public. We look forward to working together to unlock the potential benefits of AI, on a foundation of trust, safety, and security." CHAI model cards were designed to enhance transparency and accountability across the AI lifecycle. By displaying key elements of these cards on vendor profiles, Elion aims to bridge the gap between technical documentation and real-world procurement. Learn more about CHAI model cards here. About Elion: Elion is a trusted health IT marketplace and research firm dedicated to empowering healthcare organizations through technology insights and strategic guidance. By bridging the gap between healthcare leaders and innovative solutions, Elion is driving the future of healthcare delivery. For more information, visit: About CHAI: The CHAI (Coalition for Health AI) mission is to be the trusted source of guidelines for Responsible AI in Health. It aims to ensure high-quality care, foster trust among users, and meet the growing healthcare needs. As a coalition bringing together leaders and experts representing health systems, startups, government and patient advocates, CHAI has established working groups focusing on privacy and security, fairness, transparency, usefulness, and safety of AI algorithms.
Business Standard
20-05-2025
- Business
- Business Standard
Elion Technologies: 15 Years of Fire-Free Facilities Through Proactive Safety Audits
PNN New Delhi [India], May 20: With fire incidents making headlines across India in recent months--impacting hospitals, warehouses, offices, and even schools--the need for structured and regular fire safety audits has become more urgent than ever. Elion Technologies and Consulting Pvt Ltd, a leading safety audit and consulting firm, has been at the forefront of ensuring that its clients remain protected through proactive and regulation-compliant fire safety audits. Having conducted over 20,00+ fire safety audits across India in the last 15 years, Elion's track record is unmatched. What stands out: none of the regularly audited client facilities have reported any major fire incidents post-compliance. "In most fire-related tragedies, one thing is common--neglect of preventive measures," said Neha Kakkar, Business Development Manager at Elion. "Our mission is to change that. A timely audit can mean the difference between a near-miss and a disaster." Elion's fire safety audits are conducted in line with the National Building Code (NBC) 2016 Part 4, IS 2190, IS 3844, and relevant BIS standards. The scope includes: * Fire detection and alarm systems * Adequacy and condition of extinguishers * Fire hydrant and sprinkler systems * Emergency evacuation protocols * Risk identification for people, assets, and environment * Assessment of passive and active fire protection measures Industries Served: Elion has provided fire safety consulting to sectors including oil & gas, manufacturing, pharma, education, hospitality, and IT infrastructure--both in India and internationally. Notable clients include Tata Projects, Adani Group,Indian Railway, IOCL, KPMG, Hilton Hotels, and various multinational corporations with operations across India and abroad. "We don't just identify problems; we guide the client in solving them with cost-effective and standards-aligned solutions," said Rahul Arya, Fire System Expert at Elion, with over 20 years of experience. With increasing scrutiny from insurers, regulators, and global ESG norms, regular fire safety audits are no longer optional for businesses that care about reputation, safety, and operational continuity. For more information or to schedule a fire safety audit, contact Elion Technologies at mail@ or visit
Yahoo
09-04-2025
- Business
- Yahoo
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo validation and drug discovery to Renovaro's AI powered biomarker and diagnostic platform. At the core of this potential synergy is BioSymetrics' proprietary Elion platform, a cutting-edge AI and machine learning engine that has been designed to uncover complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics' Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite and improve target and biomarker identification and enables patient stratification and drug repurposing. BioSymetrics' advanced in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle biological responses with unprecedented accuracy. Through in vivo modeling, BioSymetrics has amassed a very large database of proprietary in vivo experimentation, with associated behavioral and morphological analysis. This integrated approach potentially hastens the discovery and validation of transformative therapeutics by bridging computational insights with real-world biological validation, and has enabled platform and analytic partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. By integrating Elion into Renovaro's workflow, the combined business aims to streamline the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development. 'This merger represents a pivotal step in our mission to diagnose cancer and advance precision medicine,' said David Weinstein, CEO of Renovaro. 'By combining our expertise in oncology with BioSymetrics' expertise in epilepsy and other neurological diseases, we believe that we are creating a powerful synergy that will enhance our ability to identify new therapeutic targets, validate diagnostics and accelerate precision drug development.' BioSymetrics' AI technology has been instrumental in uncovering novel disease signatures and optimizing precision medicine strategies. Through this merger, Renovaro can now access cutting-edge computational tools that are designed to enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions in oncology and neurology. 'We are excited to join forces with Renovaro to translate cutting-edge biomarker discoveries into tangible advancements in drug development,' said Anthony Iacovone, CEO of BioSymetrics. 'Our AI-driven Elion platform has the potential to significantly impact precision medicine and by aligning with Renovaro's deep expertise in immunotherapy and oncology, we believe that we can accelerate the journey from discovery to clinical application.' The combination of Renovaro and BioSymetrics underscores a shared commitment to harnessing AI and data-driven approaches to improve patient outcomes. Moving forward, the combined company will focus on integrating AI-powered biomarker discovery with innovative drug development, ultimately intended to bring more precise and effective treatments to patients worldwide. For more information, visit and About BioSymetrics BioSymetrics is a leading AI-powered drug discovery and data analytics company, focusing on phenotype-based insights to identify novel therapeutics. Its proprietary Elion platform integrates large-scale biological and clinical data to drive innovation in the pharmaceutical and healthcare industries. For more information, visit About Renovaro Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development. For more information, visit Forward-Looking Statements This press release contains statements by Renovaro Biosciences Inc. ('Renovaro', 'we', 'us', 'our' or the 'Company') that are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, our prospects, plans, business strategy and expected financial and operational results. You can identify these statements by the use of words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'should,' 'will,' 'would', 'could', 'project', 'plan', 'potential', 'designed', 'seek', 'target', variations of these terms, the negatives of such terms and similar expressions. These statements are based on certain assumptions that we have made in light of our experience in our industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. You should not rely on forward-looking statements because our actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: the success or efficacy of our pipeline, platform and fundraising; our ability to successfully integrate business that we have acquired, including BioSymetrics, or that we may acquire; our ability to achieve the benefits that we expect to realize as a result of our acquisitions, including BioSymetrics; and those other risks and uncertainties discussed in the reports we have filed with the Securities and Exchange Commission (the 'SEC'), such as our most recent Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date the statements were made. We do not undertake any obligation to update forward-looking information, except to the extent required by applicable law. Investor Relations Chris TysonExecutive Vice PresidentMZ Group - MZ North America949-491-8235RENB@ For media inquiries, please contact:karen@ in to access your portfolio
Globe and Mail
26-02-2025
- Business
- Globe and Mail
Merger Agreement with BioSymetrics to Accelerate Biomarker Identification, Enhance Drug Discovery and Expand Precision Medicine Applications in Advanced Cancer Diagnosis and Treatment
$RENB Also Secures Plus $15 Million in New Equity to Support its Operations Towards Revolutionizing Healthcare • Developing AI and Biotechnology Platforms for Early Diagnosis, Better-Targeted Treatments and Drug Discovery. • Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI). • Definitive Merger Agreement with BioSymetrics to Advance AI-Driven Biomarker Discovery and Precision Medicine in Cancer and Beyond. • $15 Million in New Equity Committed to accelerate Focus on Revolutionizing Healthcare via the Company's Established Strategies. • 2025 Shareholder Update Issued from CEO. • Plans to Attend American Association for Cancer Research (AACR), The First and Largest Cancer Research Organization, Annual Meeting in April, 2025. • Funding Approval of LUMINA Minimal Residual Disease Detection Platform for Lung Cancer Harnessing Multi-omics Biomarkers and AI. • Entered Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection. • Plans to Establish the Renovaro GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's Certified AI Healthcare Cloud Solutions. Renovaro, Inc. (Nasdaq: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development. RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care. Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine On February 26th RENB announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas. At the core of this collaboration is BioSymetrics' proprietary Elion platform, a cutting-edge AI and machine learning engine that uncovers complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics' Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite and improve target and biomarker identification and enable patient stratification and drug repurposing. BioSymetrics' advanced AI in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle biological responses with unprecedented accuracy. Through in vivo modeling BioSymetrics has amassed an incredible database of proprietary in vivo experimentation, with associated behavioral and morphological analysis. This integrated approach hastens the discovery and validation of transformative therapeutics by bridging computational insights with real-world biological validation, and has enabled platform and analytic partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. By integrating Elion into the RENB workflow, the combined entity aims to streamline the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development. BioSymetrics' AI technology has been instrumental in uncovering novel disease signatures and optimizing precision medicine strategies. Through this merger, RENB will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions. For more information on BioSymetrics visit: $15 Million in New Equity Committed RENB has also announced that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term. David Weinstein, Chief Executive Officer of Renovaro, commented, 'We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery.' Shareholder Letter and Corporate Update On January 7th RENB issued a letter to shareholders from Chief Executive Officer David Weinstein. The letter contained the following commentary: RENB recently signed a binding letter of intent to acquire Predictive Oncology (NASDAQ: POAI) that will provide with a tremendous company-owned database consisting of 150,000 frozen / live tumor samples, 20 years of drug response data, 40,000 FFPE tissue blocks, 200,000 pathology slides and digital library, and a fully certified CLIA laboratory. RENB plans to commercialize Predictive's clinical support test that assists oncologists in selecting the best therapy for their patients, and deploy their multi-omic AI system for drug discovery known as PEDAL (Patient-centric Discovery by Active Learning), a platform that combines AI technology, drug response data, and a large biobank of tumor samples to predict how different tumors will respond to various drugs. When RENB acquired GEDiCube, the rationale was that these two business segments were synergistic. This remains a core value proposition but for synergies to materialize requires structured collaboration between the two verticals: AI cancer detection and genetically enhanced cancer vaccines. There are two business developments that RENB is pursuing. Identifying a whole genome sequencer that can serve as the front end of RENB point of care cancer detection platform. GEDiCube to deploy its AI/ML analysis to discover more genes and factors in RENB Dendritic Cancer Cell Vaccine (DCCV). Incorporating these new discoveries into RENB patent filings will build shareholder value by ringfencing the DCCV platform and providing the ability to partner or license specific cancer applications. This has the potential to enhance the core three elements RENB infuses into DCCV now, allowing it to become specific for cancer types, and ultimately be available as an off the shelf solution. In the future this could facilitate early cancer detection in a doctor's office followed by the treatment of a patient with our vaccine. To gain exposure for DCCV RENB will attend the American Association for Cancer Research Annual Meeting in April 2025. For more information on $RENB visit: and Disclosure listed on the CorporateAds website Media Contact Company Name: Renovaro Inc. Contact Person: David Weinstein, CEO Email: Send Email Phone: 732-780-5036 Address: 2080 Century Park East Suite 906 City: Los Angeles State: California Country: United States Website:
Yahoo
26-02-2025
- Business
- Yahoo
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas. At the core of this collaboration is BioSymetrics' proprietary Elion platform, a cutting-edge AI and machine learning engine that uncovers complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics' Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite and improve target and biomarker identification and enable patient stratification and drug repurposing. BioSymetrics' advanced AI in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle biological responses with unprecedented accuracy. Through in vivo modeling BioSymetrics has amassed an incredible database of proprietary in vivo experimentation, with associated behavioural and morphological analysis. This integrated approach hastens the discovery and validation of transformative therapeutics by bridging computational insights with real-world biological validation, and has enabled platform and analytic partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. By integrating Elion into Renovaro's workflow, the combined entity aims to streamline the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development. 'This merger represents a pivotal step in our mission to diagnose cancer and advance precision medicine,' said David Weinstein, CEO of Renovaro. 'By combining our expertise in oncology with BioSymetrics' AI-driven biomarker discovery, we are creating a powerful synergy that will enhance our ability to identify new therapeutic targets, validate diagnostics and accelerate drug development.' BioSymetrics' AI technology has been instrumental in uncovering novel disease signatures and optimizing precision medicine strategies. Through this merger, Renovaro will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions. 'We are excited to join forces with Renovaro to translate cutting-edge biomarker discoveries into tangible advancements in drug development,' said Anthony Iacovone, CEO of BioSymetrics. 'Our AI-driven Elion platform is significantly impacting precision medicine and by aligning with Renovaro's deep expertise in immunotherapy and oncology, we can accelerate the journey from discovery to clinical application.' The merger underscores a shared commitment to harnessing AI and data-driven approaches to improve patient outcomes. Moving forward, the combined company will focus on integrating AI-powered biomarker discovery with innovative drug development, ultimately bringing more precise and effective treatments to patients worldwide. The transaction is expected to close in March 2025, subject to customary closing conditions and regulatory approvals. For more information, visit and About BioSymetrics BioSymetrics is a leading AI-powered drug discovery and data analytics company, focusing on phenotype-based insights to identify novel therapeutics. Its proprietary Elion platform integrates large-scale biological and clinical data to drive innovation in the pharmaceutical and healthcare industries. For more information, visit About RenovaroRenovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development. For more information, visit Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as 'believes,' 'plans,' 'expects,' 'aims,' 'intends,' 'potential,' or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro's most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. Investor RelationsChris TysonExecutive Vice PresidentMZ Group - MZ North America949-491-8235RENB@ For media inquiries, please contact: karen@ in to access your portfolio
